- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04579848
Methotrexate in Erosive Inflammatory Hand Osteoarthritis (MERINO)
The Methotrexate in ERosive INflammatory Osteoarthritis (MERINO) Trial: A Randomized Placebo-controlled Trial to Investigate Clinical Efficacy and Safety of Methotrexate in Erosive Inflammatory Hand Osteoarthritis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The trial will include Norwegian adult males and females with symptomatic erosive inflammatory hand osteoarthritis.
Participants will be randomized 1:1 to either:
- Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks (intervention group). Dosage can be reduced to as low as 10 mg if higher doses are not tolerated.
- Placebo (control group).
Both arms will receive folic acid 1mg daily.
The treatment duration for both groups is 52 weeks.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Ida K. Haugen, MD, PhD
- Phone Number: 95859884
- Email: ida.k.haugen@gmail.com
Study Contact Backup
- Name: Alexander Mathiessen, MD, PhD
- Phone Number: 97501889
- Email: alexander_mathiessen@hotmail.com
Study Locations
-
-
-
Oslo, Norway
- Recruiting
- Diakonhjemmet Hospital
-
Contact:
- Ida K Haugen, MD, PhD
- Phone Number: +47 95859884
- Email: ida.k.haugen@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Finger joint pain 40-80 on 0-100 visual analog scale (VAS) with insufficient pain relief from, inability to tolerate or contra-indications to oral paracetamol and/or NSAIDs, and hand symptoms (pain, aching, or stiffness) on most days the previous 6 weeks before randomization.
- Hand OA according to the American College of Rheumatology (ACR) criteria, at least 1 distal (DIP) or proximal interphalangeal (PIP) joint of the 2nd-5th finger with radiographic pre-erosive (J-phase) or erosive disease (E-phase) according to the Verbruggen-Veys anatomical phase system, and at least two DIP/PIP joints with power Doppler signal of at least grade 1 or grey-scale synovitis of at least grade 2 on ultrasound.
Exclusion Criteria:
A full list of the exclusion criteria for this study comprised the following:
Contraindications to methotrexate:
- Abnormal renal function, defined as serum creatinine >142 µmol/L in women and >168 µmol/L in men, or a glomeruli filtration rate (GFR) <40 mL/min/1.73 m2.
- Abnormal liver function, defined as transaminases above the upper normal limit, active or previous hepatitis B or C infection, or known cirrhosis
- Lung fibrosis (maximum 6 months old x-ray), active infection, or reduced hematopoiesis (i.e. anemia, leukopenia and/or thrombocytopenia).
- Planned pregnancy within 18 months after screening (men/women), and pregnancy, breastfeeding, or insufficient anti-conception therapy for female fertile participants. Contraception should be maintained during treatment and until the end of systemic exposure, i.e. 3 months after methotrexate discontinuation. Sufficient anti-conception therapy consists of intra-uterine device (coil) or hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections).
- Alcohol or other drug abuse in the last year.
- Intolerance to lactose.
- Chronic inflammatory rheumatic diseases (such as rheumatoid arthritis and psoriatic arthritis or gout), active inflammatory bowel disease, or positive rheumatoid factor or anti-CCP antibodies.
- Other severe co-morbidities such as hemochromatosis, fibromyalgia, psoriasis, blood dyscrasias, and coagulation disorders, history of malignancy (except successfully treated squamous or basal cell skin carcinoma), uncontrolled diabetes mellitus, severe hypertension, unstable ischemic heart disease, severe heart failure, severe pulmonary disease, severe and/or opportunistic infections and/or chronic infections, active tuberculosis, positive human immunodeficiency virus (HIV) status, recent stroke, bone marrow hypoplasia, or demyelinating diseases of the central nervous system.
- Other likely causes of hand symptoms: thoracic outlet syndrome, carpal tunnel disease, diabetic cheiropathy, injury in finger joints previous 6 months, or palmar tenosynovitis/trigger finger.
- Oral or intra-muscular steroids in the previous month
- Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion
- Analgesics or NSAIDs, unless stable dosage for ≥1 month.
- Symptomatic slow-acting drugs for OA (SYSADOA), unless stable dose for ≥3 months and require stable dose throughout the study.
- Disease-modifying osteoarthritis drugs (DMOADs) previous three months.
- Scheduled hand surgery during study participation.
- Planning to start other treatments for hand OA in the study participation period.
- Not able to adhere to the study visit schedule and protocol requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Methotrexate
Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks. Additional Folic acid 1mg prescribed daily. |
Methotrexate 2.5mg oral tablet.
Folic acid
|
Placebo Comparator: Placebo
3 capsules per week for two weeks, followed by 4 capsules the remaining weeks. Additional Folic acid 1mg prescribed daily. |
Placebo capsule
Folic acid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Finger pain on a visual analogue scale
Time Frame: 6 months
|
Difference in self-reported finger joint pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OMERACT-OARSI responder criteria
Time Frame: Month 1, 3, 6, 9 and 12.
|
Fulfillment of Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) responder criteria.
|
Month 1, 3, 6, 9 and 12.
|
Finger pain on a visual analogue scale
Time Frame: Month 1, 3, 6, 9 and 12.
|
Self-reported finger pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome.
|
Month 1, 3, 6, 9 and 12.
|
Thumb pain on a visual analogue scale
Time Frame: Month 1, 3, 6, 9 and 12.
|
Self-reported thumb pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome.
|
Month 1, 3, 6, 9 and 12.
|
Pain most painful finger joint on a visual analogue scale
Time Frame: Month 1, 3, 6, 9 and 12.
|
Pain most painful finger joint last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.
|
Month 1, 3, 6, 9 and 12.
|
Patient-reported disease activity on a visual analogue scale
Time Frame: Month 1, 3, 6, 9 and 12.
|
Patient-reported disease activity last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.
|
Month 1, 3, 6, 9 and 12.
|
AUSCAN
Time Frame: Month 1, 3, 6, 9 and 12.
|
Australian/Canadian hand index (AUSCAN), sum score 0-60, higher value indicate worse outcome.
|
Month 1, 3, 6, 9 and 12.
|
EQ-5D
Time Frame: Month 1, 3, 6, 9 and 12.
|
Quality-adjusted life years (QALYs) based on the health-related utility scores measured by the generic instrument EuroQol 5 dimensions (EQ-5D), sum score 5-35, higher value indicate worse outcome, in addition to a 0-100 visual analogue scale where higher value indicate better outcome.
|
Month 1, 3, 6, 9 and 12.
|
Concomitant medication
Time Frame: Month 1, 3, 6, 9 and 12.
|
Concomitant medication
|
Month 1, 3, 6, 9 and 12.
|
Tender and swollen joints
Time Frame: Month 1, 3, 6, 9 and 12.
|
Number of tender and swollen joints (range 0-30), higher values indicate more affected joints.
|
Month 1, 3, 6, 9 and 12.
|
Grip strength
Time Frame: Month 1, 3, 6, 9 and 12.
|
Grip strength (in kg; using a hand dynamometer)
|
Month 1, 3, 6, 9 and 12.
|
Pain sensitization
Time Frame: Month 1, 3, 6, 9 and 12.
|
Pain sensitization: Pressure Pain Thresholds (PPT) by digital algometer; temporal summation by punctate probes; Conditioned Pain Modulation (CPM) by blood pressure ischemic test.
|
Month 1, 3, 6, 9 and 12.
|
Ultrasound
Time Frame: Month 1, 3, 6, 9 and 12.
|
Ultrasound: number of finger joints with synovial thickening and power Doppler signals.
|
Month 1, 3, 6, 9 and 12.
|
Hand diagram pain
Time Frame: Month 6.
|
Finger pain and thumb base pain (yes/no) on hand diagram
|
Month 6.
|
MHOQ
Time Frame: Month 6.
|
Michigan Hand Outcomes Questionnaire (MHOQ) pain and physical function subscales; function subscale range 10-50, higher value indicate worse outcome; task subscale range 17-85, higher value indicate worse outcome; work subscale range 5-25, higher value indicate worse outcome; pain subscale range 10-48, higher value indicate better outcome.
|
Month 6.
|
Morning stiffness fingers
Time Frame: Month 6.
|
Duration of morning stiffness in finger joints in minutes, higher value indicate worse outcome.
|
Month 6.
|
Morning stiffness thumbs
Time Frame: Month 6.
|
Duration of morning stiffness in thumb base joints in minutes, higher value indicate worse outcome.
|
Month 6.
|
HADS
Time Frame: Month 6.
|
Hospital Anxiety and Depression Scales (HADS), range 0-42, higher value indicate worse outcome.
|
Month 6.
|
PCS
Time Frame: Month 6.
|
Pain Catastrophizing Scale (PCS), range 0-12, higher value indicate worse outcome.
|
Month 6.
|
PSQ
Time Frame: Month 6.
|
Pain Sensitivity Questionnaire (PSQ), range 0-170, higher value indicate worse outcome.
|
Month 6.
|
KOOS-12
Time Frame: Month 6.
|
Knee injury and Osteoarthritis Outcome Score (KOOS)-12, range 12-60, higher value indicate worse outcome.
|
Month 6.
|
HOOS-12
Time Frame: Month 6.
|
Hip disability and Osteoarthritis Outcome Score (HOOS)-12, range 12-60, higher value indicate worse outcome.
|
Month 6.
|
Radiographs: Kellgren Lawrence
Time Frame: Month 6 and 12
|
Conventional radiographs: change in radiographic severity according to Kellgren-Lawrence scale, range 0-4 in each finger joints, in total 30 joints; higher value indicate worse outcome.
|
Month 6 and 12
|
Radiographs: Verbruggen-Veys anatomical phase scoring system
Time Frame: Month 6 and 12
|
Conventional radiographs: change in radiographic severity in finger joints according to Verbruggen-Veys anatomical phase scoring system, range 1-5 in each finger joint, in total 30 finger joints; higher value indicate worse outcome.
|
Month 6 and 12
|
Radiographs: OARSI atlas
Time Frame: Month 6 and 12
|
Conventional radiographs: change in radiographic severity according to the Osteoarthritis Research Society International (OARSI) atlas for the presence/severity of osteophytes, joint space narrowing and erosions.
|
Month 6 and 12
|
Soluble biomarkers of extracellular matrix turnover
Time Frame: Month 6 and 12
|
Markers of collagen degradation (s-COMP, s-C1M, s-C2M, s-C3M, s-CTX1, sHA), collagen synthesis (s-proC2), aggrecan degradation (s-huARGS) and inflammation (s-calprotectin, s- vimentin, s-hsCRP and s-CRPM); Inflammatory cytokines (IL-1β, IL-1ra, IL-4, IL-6, IL-10, IL-12, IL-17, IL-18, IL-21, IFN-γ, TNF-α, VEGF, GM-CSF, CCL2, CCL3, CCL4, CXCL10) and hormones (leptin and resistin).
|
Month 6 and 12
|
Adverse events
Time Frame: Through study completion, maximum 12 months, in addition to 3 months after end of treatment.
|
Number of adverse events, serious adverse events, and withdrawals because of adverse events.
|
Through study completion, maximum 12 months, in addition to 3 months after end of treatment.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sub-study: biopsy of knee OA
Time Frame: Month 6
|
Change in synovial cellular composition and gene expression with single-cell RNA sequencing analyses; subgroup analyses, n=16 patients
|
Month 6
|
Sub-study: knee pain on a visual analogue scale
Time Frame: Month 6
|
Self-reported knee pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome.
|
Month 6
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Tore K Kvien, MD, PhD, Professor Em.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Micronutrients
- Vitamins
- Reproductive Control Agents
- Vitamin B Complex
- Hematinics
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
- Folic Acid
Other Study ID Numbers
- DIA2020-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The trialists and other study personnel that conceive of the study, and then plan, manage, monitor, analyze and publish it, will have access to IPD. Participants' identification code numbers are de-identified by replacing the original code number with a new random code number. Only the PI and project coordinator have access to this code.
The protocol, SAP, ICF, and CSR will be shared with regulatory agents as required.
Study Data/Documents
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hand Osteoarthritis
-
University of ZurichWithdrawnHand Osteoarthritis | Wrist Injuries | Wrist Fracture | Hand Injury Wrist | Wrist Arthritis | Hand Fracture | Hand Sprain
-
FoU Center SpenshultThe Swedish Rheumatism AssActive, not recruitingOsteoarthritis, Knee | Osteoarthritis Hand | Osteoarthritis GeneralizedSweden
-
Henning BliddalCompletedOsteoarthritis Hand | Osteoarthritis FingerDenmark
-
Vita CareTegos S.A.CompletedOsteoarthritis | Osteoarthritis Hand | Osteoarthritis Finger | Osteoarthritis Both HandsBrazil
-
Diakonhjemmet HospitalNot yet recruitingHand Osteoarthritis | Erosive OsteoarthritisNorway
-
Cedars-Sinai Medical CenterMusculoskeletal Transplant FoundationRecruitingOsteoarthritis HandUnited States
-
BioibericaUnknown
-
Diakonhjemmet HospitalNorwegian Fund for Postgraduate Training in PhysiotherapyCompleted
-
Guang'anmen Hospital of China Academy of Chinese...Recruiting
-
University Hospital, MontpellierRecruitingHand OsteoarthritisFrance
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States